BlueRock Therapeutics announced the dose administration for the first patient in a Phase I, open-label study of PSC-derived dopaminergic neurons in patients with advanced Parkinson’s disease.
[BlueRock Therapeutics]
Sorry, but the selected Zotpress account can't be found.
